Dr. Douglas Hay has over 30 years pharmaceutical regulatory experience. Prior to joining the company Dr. Hay was a co-founder of Phyxius Pharma, Inc. where he served as Vice President of Regulatory Affairs. Previously, Dr. Hay lead positions in global regulatory affairs at The Medicines Company and Shire Pharmaceuticals. He spent most of his career at Bristol Myers Squibb where he advanced to Vice President, Global Regulatory Sciences. This experience spans drug development (Phase 1-4) in numerous therapeutic areas, including the development of new chemical entities and novel biologics. Dr. Hay’s experience has included responsibility for development projects in virtually all major cardiovascular classes, including development/registration programs for Capoten, Monopril, Avapro, Plavix, and Angiomax. Doug received his AB degree in Biology from University of California, Riverside, MS in biology at California State University, Long Beach, and PhD (physiology emphasis) from Northern Arizona University.
